Pair will end partnership on cancer drug, leaving GTx with rights, and costs, of development.
Kelsey Swanekamp, Forbes
Mon, 03/15/2010 - 3:10pm
Pair will end partnership on cancer drug, leaving GTx with rights, and costs, of development.